Legal & General Group Plc Has $148.04 Million Holdings in Illumina, Inc. $ILMN

Legal & General Group Plc lessened its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 9.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 1,128,669 shares of the life sciences company’s stock after selling 116,019 shares during the quarter. Legal & General Group Plc’s holdings in Illumina were worth $148,036,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of ILMN. Capital World Investors grew its holdings in shares of Illumina by 20.0% during the 3rd quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock worth $1,897,178,000 after purchasing an additional 3,331,542 shares in the last quarter. Nordea Investment Management AB grew its holdings in shares of Illumina by 2,792.2% during the 4th quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock worth $124,145,000 after purchasing an additional 911,843 shares in the last quarter. Massachusetts Financial Services Co. MA acquired a new stake in shares of Illumina during the 4th quarter worth approximately $73,532,000. State Street Corp grew its holdings in shares of Illumina by 6.8% during the 3rd quarter. State Street Corp now owns 5,999,790 shares of the life sciences company’s stock worth $569,800,000 after purchasing an additional 382,520 shares in the last quarter. Finally, Duquesne Family Office LLC acquired a new stake in shares of Illumina during the 2nd quarter worth approximately $28,682,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Key Stories Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina and SPT Labtech launched fireflyGO, a new automation platform designed to make targeted oncology research faster, simpler, and more scalable. The product is integrated with Illumina’s MiSeq i100 Series and could help broaden adoption of its sequencing workflow. Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
• Positive Sentiment: Illumina also introduced a distributed whole-genome sequencing solution for MRD research, expanding its oncology portfolio and making it easier for more labs to adopt molecular residual disease testing in clinical research. That supports the company’s long-term growth narrative in precision oncology. Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
• Neutral Sentiment: A separate marketwide report noted that the broader stock market reached fresh highs on upbeat macro news. While this may be helping overall sentiment, it is not specific to Illumina’s business. Dow Jones Futures: Stock Market Hits Highs On U.S.-Iran Deal; Dell Surges On Earnings
• Neutral Sentiment: One article flagged Illumina as a strong momentum stock, which may reinforce positive trader sentiment, but it did not include new fundamental information. Here’s Why Illumina (ILMN) is a Strong Momentum Stock

Illumina Stock Up 5.7%

ILMN opened at $158.70 on Friday. The firm’s 50-day simple moving average is $132.92 and its 200-day simple moving average is $131.80. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. Illumina, Inc. has a twelve month low of $78.79 and a twelve month high of $158.79. The firm has a market cap of $24.01 billion, a price-to-earnings ratio of 28.85, a PEG ratio of 2.49 and a beta of 1.42.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The business had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the prior year, the firm earned $0.97 EPS. The firm’s quarterly revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Equities research analysts anticipate that Illumina, Inc. will post 5.2 EPS for the current fiscal year.

Insider Buying and Selling at Illumina

In other Illumina news, Director Keith A. Meister sold 225,067 shares of Illumina stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $145.55, for a total value of $32,758,501.85. Following the completion of the transaction, the director owned 3,604,441 shares in the company, valued at approximately $524,626,387.55. The trade was a 5.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Christensen Jakob Wedel sold 700 shares of Illumina stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total value of $97,328.00. Following the completion of the transaction, the senior vice president owned 15,056 shares of the company’s stock, valued at approximately $2,093,386.24. The trade was a 4.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 330,160 shares of company stock valued at $48,028,308. Corporate insiders own 2.90% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on ILMN shares. Citigroup boosted their price target on Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research note on Monday, May 4th. Barclays boosted their price target on Illumina from $110.00 to $122.00 and gave the company an “underweight” rating in a research note on Friday, May 1st. Robert W. Baird set a $137.00 price target on Illumina in a research note on Friday, February 6th. JPMorgan Chase & Co. boosted their price target on Illumina from $120.00 to $125.00 and gave the company a “neutral” rating in a research note on Friday, May 1st. Finally, Daiwa Securities Group raised shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price on the stock in a report on Thursday, May 14th. Seven analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Illumina presently has an average rating of “Hold” and an average target price of $137.75.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.